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In recent years, polymeric micelles are attracting much interest in the research 
field of drug delivery due to their easy preparation, based on the self-assembly in 
aqueous solution of amphiphilic block polymers, and the controllable modification of 
their properties. Taking advantage of the so-called enhanced permeability and retention 
(EPR) effect, which is due to leaky blood vasculature and impaired lymph drainage of 
solid tumors, micelles can specifically accumulate in tumor tissue. Moreover, the 
targeting of nanocarriers can be further improved by modifying their surface with 
specific ligands having high binding ability against receptors overexpressed on cancer 
cells. In addition, the specific stimuli in the microenvironment of tumor tissues can be 
used for tumor selective release of the loaded drugs. Thus, by increasing the specificity 
of drug delivery to tumor tissues, nanocarriers can minimize the off-targeting effects to 
and maximize the efficacy of the treatments. The review result of each thesis chapter is 
shown in the following. 
In the First Chapter, the background and goal of this study was introduced. As 
one type of nanocarrier with many advantages over others, polymeric micelle is 
introduced. The targeting method of micelle and its functionalization with stimuli 
responsibility is also discussed. Challenging to existing antibody-drug conjugate (ADC), 
a new method of using micelle to deliver prodrugs used in ADCs is come up. Also, the 
significance of this research is pointed out. 
In the Second Chapter, a micelle platform is designed to investigate the 
prodrug activation profile. In conventional research, the prodrug activation is measured 
by end-point methods and the information about microdistribution is hard to get due to 
the intrinsic properties of ADC prodrugs. However, when Hoechst is used as 
DNA-targeting probe, the prodrug activation process can be easily followed in real time 
with the information about microdistribution. With this Hoechst-loaded micelle, a 
consistent conclusion about the cleavability of peptide linkers used in ADC prodrugs, 
which is valine-citrulline has more selectivity over valine-alanine, is proved. Also, this 
Hoechst micelle supplies important information about prodrug activation and 
microdistribution in organs and tumor, which can be used for the following research. 
In the Third Chapter, the installation technique of installing Fab on micelle 
surface is discussed. As the purpose of this research is to deliver ADC prodrugs in 
micelles, it is reasonable to modify micelle surface with antibody or its binding 
fragment Fab. Here, it is proved that the length of cross-linker for Fab conjugation, 
which is the number of PEG units, affect installation efficiency. Also, it is pointed out 
that the cross-linker length does not affect micelle binding and cellular uptake, as long 
as the Fab density is kept consistent. However, when the Fab density increases from 
30% to 60%, the cellular uptake decreases significantly. 
In the Fourth Chapter, the results obtained from Chapter 2 and chapter 3 are 
used to design a therapeutic micelle, which is conjugated with MMAE prodrug in the 
core and modified with Fab on the surface. MMAE is a potent drug and its ADC 
product has been approved. Here, by delivering MMAE prodrug in micelle, the 
antibody utilization efficiency, which is indicated by Fab/MMAE ratio, has a 40 fold 
increment. In addition, the Fab modified MMAE micelle has comparable cytotoxicity 
with ADC, long retention in tumor tissue, good efficacy on tumor growth inhibition and 
excellent safety under multiple treatment. 
In the Fifth Chapter, a functionalized micelle is introduced, which has 
responsiveness over the acidic pH environment in the cell endosome. As a general issue 
of enzymatically activated prodrug in micelle is the hindered access of enzyme exerted 
by PEG shell, a pH sensitive function is introduced for micelles by modifying polymer 
side chains with imidazole moieties. It is successfully proved that after introduction of 
pH sensitivity, micelle can undergo reversible dissociation under endosomal pH. Also, 
the prodrug activation is accelerated and the cytotoxicity is enhanced, both of which can 
be explained by the fact that enzyme has more access to cleavable linkers when the 
micelle dissociated into unimers. 
In the Sixth Chapter, general conclusions are presented and the future 
application of this micelle platform in clinical therapy is discussed. 
In the thesis mentioned above, a versatile polymeric micelle platform 
containing furans conjugating ADC prodrugs through Diels-Alder reaction was 
successfully developed. This platform provides a safe and effective strategy for 
developing carrier systems for highly potent anticancer agents, which have been 
delivered by antibodies so far, thereby, opening new opportunities for therapies capable 
of eradicating tumors while avoiding toxicities. We have applied a patent for developing 
these systems, and the venture company Nanocarrier is interested to take them to the 
clinic. I believe these findings will make a strong impact in the field of bioengineering, 
particularly in nanomedicine, promoting the rise of potent anticancer systems. 
According to the reviews, this thesis is eligible for applying a diploma of 
Ph.D (engineering). 
